Allogene Therapeutics (ALLO) Stock Drops Over 5% Amid Market Activity

Company Overview - Allogene Therapeutics, Inc. is a clinical-stage biotechnology firm specializing in immuno-oncology, developing genetically engineered allogeneic T-cell products for cancer and autoimmune diseases [2] - The company's approach utilizes healthy donor cells, which broadens patient eligibility and scalability [2] - Key projects target lymphoma, leukemia, autoimmune diseases, and solid tumors, with revenue primarily derived from partnerships and licensing agreements [2] Financial Performance - Allogene Therapeutics recorded no revenue and a net loss of $66.36 million, with an earnings per share (EPS) of -$0.35 [1] - The company reported a gross loss of $3.64 million, resulting in a price-to-earnings (P/E) ratio of -1.60 [1] - The stock price fell 5.06% to $2.54 per share, with a trading volume of 1.41 million shares and a turnover rate of 0.67% [1] Market Sentiment - Among the 18 institutions covering Allogene Therapeutics, 72% recommended buying, 28% suggested holding, and none advised selling [1] - The broader biotechnology sector experienced a decline of 0.96%, with related stocks showing varied performances [2] - Stocks with high volatility included Pasithea Therapeutics Corp., Tevogen Bio Holdings Inc., and Apollomics Inc. [2]